Skip to main content
SpringerLink
Log in

Maligne Erkrankungen des Gastrointestinaltrakts bei alten Patienten

Malignant diseases of the gastrointestinal tract in older patients

  • Schwerpunkt
  • Published:
Der Gastroenterologe Aims and scope

Zusammenfassung

Maligne Erkrankungen des Gastrointestinaltrakts sind typische Erkrankungen alter Menschen. Die gesundheitliche Situation alter Menschen variiert erheblich, und damit auch die Belastbarkeit für die Therapie. Alter per se ist aber kein Grund für einen therapeutischen Nihilismus. Vielmehr gilt es, die individuelle Belastbarkeit der Patienten im Rahmen eines strukturierten geriatrischen Assessments zu erfassen. Der Fokus der Arbeit liegt auf der Darstellung medikamentöser tumorspezifischer therapeutischer Optionen.

Abstract

Malignancies of the gastrointestinal tract are typical diseases occurring in older people. The overall health situation of older people varies widely and as a consequence so does the tolerance of treatment. Age itself is not a reason for therapeutic nihilism. A comprehensive geriatric assessment can help to judge tolerance and potential benefits of treatment. The following article focuses on medical tumour-specific therapeutic options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Sreedharan A, Harris K, Crellin A et al (2009) Interventions for dysphagia in oesophageal cancer. Cochrane Database Syst Rev 7: CD005048

    Google Scholar 

  2. Lewis JH et al (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21: 1383–1389

    Article  PubMed  Google Scholar 

  3. Stuck AE et al (1993) Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet 342(8878): 1032–1036

    Article  PubMed  CAS  Google Scholar 

  4. Repetto L et al (1998) Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions [see comments]. Cancer 82: 760–765

    Article  PubMed  CAS  Google Scholar 

  5. Extermann M et al (1998) Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16: 1582–15827

    PubMed  CAS  Google Scholar 

  6. Extermann M et al (2004) A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit Rev Oncol Hematol 49: 69–75

    Article  PubMed  Google Scholar 

  7. Freyer G et al (2005) Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol 16: 1795–1800

    Article  PubMed  CAS  Google Scholar 

  8. Wedding U (2010) Chances and limitations of chemotherapy in elderly patients. Internist (Berl) 51: 402, 404–6, 408–409

    Google Scholar 

  9. Pallis AG et al (2010) EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer 46: 1502–1513

    Article  PubMed  CAS  Google Scholar 

  10. Pallis AG et al (2010) Questionnaires and instruments for a multidimensional assessment of the older cancer patient: what clinicians need to know? Eur J Cancer 46: 1019–1025

    Article  PubMed  CAS  Google Scholar 

  11. Homs MY et al (2006) Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction. Cochrane Database Syst Rev: CD004063

    Google Scholar 

  12. Semrau R et al (2012) Radiotherapy in elderly patients with inoperable esophageal cancer: is there a benefit? Strahlenther Onkol 188(9)226–234

    Google Scholar 

  13. Rupinski M et al (2011) Randomized comparison of three palliative regimens including brachytherapy, photodynamic therapy, and APC in patients with malignant dysphagia (CONSORT 1a) (Revised II). Am J Gastroenterol 106: 1612–1620

    Article  PubMed  CAS  Google Scholar 

  14. Wagner AD, Wedding U (2009) Advances in the pharmacological treatment of gastro-oesophageal cancer. Drugs Aging 26: 627–646

    Article  PubMed  CAS  Google Scholar 

  15. Cunningham D et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11–20

    Article  PubMed  CAS  Google Scholar 

  16. Glimelius B et al (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8: 163–168

    Article  PubMed  CAS  Google Scholar 

  17. Cunningham D et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358: 36–46

    Article  PubMed  CAS  Google Scholar 

  18. Al-Batran SE et al (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26: 1435–1442

    Article  PubMed  CAS  Google Scholar 

  19. Moehler M et al (2011) German S3-guideline „Diagnosis and treatment of esophagogastric cancer“. Z Gastroenterol 49: 461–531

    Article  PubMed  CAS  Google Scholar 

  20. Van Cutsem E et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24: 4991–4997

    Article  Google Scholar 

  21. Wagner AD et al (2007) Docetaxel for advanced gastric cancer? J Clin Oncol 25: 2490–2491 (author reply 2491–2493)

    Article  PubMed  Google Scholar 

  22. Hofheinz RD et al (2010) Population-based patterns of care in the first-line treatment of patients with advanced esophagogastric adenocarcinoma in Germany. Onkologie 33: 512–518

    Article  PubMed  Google Scholar 

  23. Oettle H et al (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297: 267–277

    Article  PubMed  CAS  Google Scholar 

  24. Burris HA III et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403–2413

    PubMed  CAS  Google Scholar 

  25. Heinemann V et al (2008) Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 8: 82

    Article  PubMed  Google Scholar 

  26. Moore MJ et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960–1966

    Article  PubMed  CAS  Google Scholar 

  27. Conroy T et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817–1825

    Article  PubMed  CAS  Google Scholar 

  28. Pelzer U et al (2011) Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 47: 1676–1681

    Article  PubMed  CAS  Google Scholar 

  29. Kohne CH et al (2002) Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13: 308–317

    Article  PubMed  CAS  Google Scholar 

  30. Papamichael D et al (2009) Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol 20: 5–16

    Article  PubMed  CAS  Google Scholar 

  31. Sargent DJ et al (2005) Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23: 8664–8670

    Article  PubMed  Google Scholar 

  32. Etzioni DA, El-Khoueiry AB, Beart RW Jr (2008) Rates and predictors of chemotherapy use for stage III colon cancer: a systematic review. Cancer 113: 3279–3289

    Article  PubMed  Google Scholar 

  33. Keating NL et al (2008) Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? J Clin Oncol 26: 2532–2537

    Article  PubMed  Google Scholar 

  34. Schmiegel W et al (2008) Update S3-guideline „colorectal cancer“ 2008. Z Gastroenterol 46: 799–840

    Article  PubMed  CAS  Google Scholar 

  35. McCleary (2009) Impact of older age on the efficacy of newer adjuvant therapies in ( 12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database. J Clin Oncol

  36. Grothey A et al (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26: 5326–5334

    Article  PubMed  CAS  Google Scholar 

  37. Grothey A et al (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22: 1209–1214

    Article  PubMed  CAS  Google Scholar 

  38. Seymour MT et al (2011) Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 377(9779): 1749–1759

    Article  PubMed  CAS  Google Scholar 

  39. Wedding U, Nitschmann S (2012) Chemotherapie bei älteren, gebrechlichen Patienten mit fortgeschrittenem kolorektalem Karzinom. Internist (in press)

  40. Jonker DJ et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040–2048

    Article  PubMed  CAS  Google Scholar 

  41. Asmis TR et al (2011) Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC) – results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Ann Oncol 22: 118–126

    Article  PubMed  CAS  Google Scholar 

  42. RKI/GEKID (Hrsg) (2012) Krebs in Deutschland 2007/2008. Berlin 2012

Download references

Interessenkonflikt

Der Autor weist auf folgende Beziehungen hin: Beratungstätigkeit für Janssen-Cilag, Fresenius-Biotech; Honorare von Janssen-Cilag, Sanofi, Roche, Amgen, Novartis, Pro-Starkan, Shire, Chugai, Dresden International University; Finanzierung wissenschaftlicher Untersuchungen durch Janssen-Cilag.

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin II, Abteilung Palliativmedizin, Universitätsklinikum Jena, Erlanger Allee 101, 07747, Jena, Deutschland

    U. Wedding

Authors
  1. U. Wedding
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U. Wedding.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wedding, U. Maligne Erkrankungen des Gastrointestinaltrakts bei alten Patienten. Gastroenterologe 7, 326–332 (2012). https://doi.org/10.1007/s11377-012-0664-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11377-012-0664-z

Schlüsselwörter

Keywords

Search

Navigation